Breaking News Instant updates and real-time market news.

MRK

Merck

$61.66

-0.27 (-0.44%)

06:47
10/13/16
10/13
06:47
10/13/16
06:47

Merck upgraded to Buy from Neutral at BofA/Merrill

BofA/Merrill analyst Colin Bristow upgraded Merck to Buy and raised its price target to $70 from $57 to reflect its opportunity in first line lung cancer. Bristow significantly raised his Keytruda sales estmate to 7.5B from $5.5B following Merck's first line lung cancer data presentations at ESMO over the weekend and feedback from experts. He expects Keytruda to receive early approval/launch in first line NSCLC from the December 24 PDUFA and to become the standard of care in the identified label and further upside from chemo combo.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$61.66

-0.27 (-0.44%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

12:16
12/09/16
12/09
12:16
12/09/16
12:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:16
12/09/16
12/09
12:16
12/09/16
12:16
Technical Analysis
NASDAQ market internals summary »

Volume is lighter for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITIC

Investors Title Company

$155.05

1.15 (0.75%)

12:15
12/09/16
12/09
12:15
12/09/16
12:15
Hot Stocks
Breaking Hot Stocks news story on Investors Title Company »

Investors Title Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$109.53

1.1 (1.01%)

12:14
12/09/16
12/09
12:14
12/09/16
12:14
Hot Stocks
USW affirms 1,300 Carrier jobs still going to Mexico, only 730 jobs staying »

The United Steelworkers,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ITIC

Investors Title Company

$155.05

1.15 (0.75%)

12:10
12/09/16
12/09
12:10
12/09/16
12:10
Hot Stocks
Breaking Hot Stocks news story on Investors Title Company »

Investors Title Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVN

InvenSense

$10.44

2.17 (26.24%)

12:10
12/09/16
12/09
12:10
12/09/16
12:10
Options
Sweep call buyers in Invensense before a trading halt »

Sweep call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

PBH

Prestige Brands

$47.19

0.66 (1.42%)

12:10
12/09/16
12/09
12:10
12/09/16
12:10
Hot Stocks
Breaking Hot Stocks news story on Prestige Brands »

Manor Road Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

PPC

Pilgrim's Pride

$18.30

-0.08 (-0.44%)

, HRL

Hormel Foods

$34.24

0.15 (0.44%)

12:09
12/09/16
12/09
12:09
12/09/16
12:09
Hot Stocks
USDA raises red meat and poultry production forecast for 2016 »

In the World Agricultural…

PPC

Pilgrim's Pride

$18.30

-0.08 (-0.44%)

HRL

Hormel Foods

$34.24

0.15 (0.44%)

SAFM

Sanderson Farms

$85.38

-0.88 (-1.02%)

TSN

Tyson Foods

$60.99

-0.605 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 15

    Dec

ANDE

Andersons

$42.25

0.95 (2.30%)

, POT

Potash

$19.67

0.39 (2.02%)

12:07
12/09/16
12/09
12:07
12/09/16
12:07
Hot Stocks
USDA U.S. wheat, corn estimates unchanged in December report »

In the World Agricultural…

ANDE

Andersons

$42.25

0.95 (2.30%)

POT

Potash

$19.67

0.39 (2.02%)

MOS

Mosaic

$30.85

0.6741 (2.23%)

DD

DuPont

$74.85

0.165 (0.22%)

SYT

Syngenta

$80.25

0.2 (0.25%)

CMP

Compass Minerals

$80.41

-0.09 (-0.11%)

CF

CF Industries

$30.25

-0.12 (-0.40%)

AGU

Agrium

$108.81

2.16 (2.03%)

BG

Bunge

$73.41

0.01 (0.01%)

MON

Monsanto

$104.79

0.09 (0.09%)

ADM

Archer Daniels

$46.32

0.35 (0.76%)

IPI

Intrepid Potash

$2.68

0.29 (12.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 27

    Jan

MMYT

MakeMyTrip

$23.85

-0.7 (-2.85%)

12:06
12/09/16
12/09
12:06
12/09/16
12:06
Hot Stocks
Breaking Hot Stocks news story on MakeMyTrip »

Capital World Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEP

NextEra Energy Partners

$25.25

0.3645 (1.46%)

12:05
12/09/16
12/09
12:05
12/09/16
12:05
Hot Stocks
Breaking Hot Stocks news story on NextEra Energy Partners »

Neuberger Berman reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDX

Celldex

$3.74

-0.02 (-0.53%)

12:05
12/09/16
12/09
12:05
12/09/16
12:05
Hot Stocks
Breaking Hot Stocks news story on Celldex »

KLP Enterprises reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSX

Phillips 66

$87.35

-0.28 (-0.32%)

, CVX

Chevron

$115.51

0.3406 (0.30%)

12:04
12/09/16
12/09
12:04
12/09/16
12:04
Hot Stocks
Phillips 66 announces 2017 capital budget of $2.7B »

Phillips 66 (PSX)…

PSX

Phillips 66

$87.35

-0.28 (-0.32%)

CVX

Chevron

$115.51

0.3406 (0.30%)

DPM

DCP Midstream

$35.39

0.225 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CME

CME Group

$122.29

1.44 (1.19%)

12:02
12/09/16
12/09
12:02
12/09/16
12:02
Hot Stocks
CME Group appoints Julie Winkler as Chief Commercial Officer »

CME Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTPH

Tetraphase

$4.63

0.14 (3.12%)

12:01
12/09/16
12/09
12:01
12/09/16
12:01
Technical Analysis
Tetraphase moves higher on unconfirmed takeover chatter »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$21.57

0.66 (3.16%)

12:00
12/09/16
12/09
12:00
12/09/16
12:00
Options
Arconic attracts bullish flow »

Arconic attracts bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

NRE

Northstar Realty Europe Corp.

$12.19

0.42 (3.57%)

, NSAM

NorthStar Asset Management

$15.16

0.16 (1.07%)

11:59
12/09/16
12/09
11:59
12/09/16
11:59
Periodicals
Bow Street offers to buy Northstar Realty Europe for $13/share, Reuters reports »

Bow Street, a hedge fund…

NRE

Northstar Realty Europe Corp.

$12.19

0.42 (3.57%)

NSAM

NorthStar Asset Management

$15.16

0.16 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

TTPH

Tetraphase

$4.63

0.14 (3.12%)

11:57
12/09/16
12/09
11:57
12/09/16
11:57
Rumors
Rumor moving shares of Tetraphase »

Rumor: Tetraphase moves…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVN

InvenSense

$8.33

0.06 (0.73%)

11:55
12/09/16
12/09
11:55
12/09/16
11:55
Periodicals
Japan's TDK in talks to acquire InvenSense, Reuters reports »

Japan's TDK Corp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

SHLD

Sears

$12.76

0.64 (5.28%)

11:55
12/09/16
12/09
11:55
12/09/16
11:55
Options
Sears put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVN

InvenSense

$8.34

0.07 (0.85%)

11:53
12/09/16
12/09
11:53
12/09/16
11:53
Hot Stocks
Breaking Hot Stocks news story on InvenSense »

Invensense trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

INSW

International Seaways

$14.21

0.67 (4.95%)

11:50
12/09/16
12/09
11:50
12/09/16
11:50
Hot Stocks
Breaking Hot Stocks news story on International Seaways »

BlueMountain Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVN

InvenSense

$8.34

0.065 (0.79%)

11:48
12/09/16
12/09
11:48
12/09/16
11:48
Periodicals
Breaking Periodicals news story on InvenSense »

InvenSense in acquistion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

INVN

InvenSense

$8.34

0.065 (0.79%)

11:48
12/09/16
12/09
11:48
12/09/16
11:48
Hot Stocks
Breaking Hot Stocks news story on InvenSense »

InvenSense halted for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

MDCO

The Medicines Co.

$32.82

-0.55 (-1.65%)

11:47
12/09/16
12/09
11:47
12/09/16
11:47
Hot Stocks
The Medicines Co. executive buys 105,500 shares of stock »

The Medicines Co. Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.